Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) ended 2025 with revenue of $17.3 billion, up 4$16.5 billion in 2024. GAAP net earnings per share was $2.93, above the analysts’ expectations of$2.65 per share. The share price was down 3% in pre-market trading. Teva issued full guidance for 2026 of $16.4-16.8 billion revenue, EBITDA of$5-5.3 billion. And earnings per share of $2.55-2.65. The 2026 revenue forecast is lower than the analyst consensus, with the mid-range of the earnings pe ...